Breast Cancer Coverage from Every Angle

GeparSepto Trial: Long-Term Results With Nab-paclitaxel in Early Breast Cancer

By: Sarah Campen, PharmD
Posted: Tuesday, December 3, 2019

In patients with early breast cancer, treatment with nab-paclitaxel significantly improved invasive disease–free survival when compared with solvent-based paclitaxel, according to the long-term results of the GeparSepto trial. Initial findings from the study had revealed a higher pathologic complete response rate in patients receiving nab-paclitaxel as well.

“The long-term results support the use of nab-paclitaxel [at] 125 mg/m2 instead of solvent-based paclitaxel in patients with early breast cancer,” stated Michael Untch, MD, PhD, of the Helios Hospital Berlin-Buch, Berlin, and colleagues. The latest findings of the prospective phase III study were published in the Journal of Clinical Oncology.

A total of 1,206 patients with histologically confirmed primary breast cancer were randomly assigned to 12 weeks of weekly nab-paclitaxel (n = 606) or solvent-based paclitaxel (n = 600), followed in both arms by epirubicin plus cyclophosphamide every 3 weeks. Following a study amendment on the results of a preplanned interim safety analysis, the dose of nab-paclitaxel was decreased to 125 mg/m2. Women with HER2-positive disease also received trastuzumab and pertuzumab for 1 year with the assigned chemotherapy.

After 4 years of follow-up, patients treated with nab-paclitaxel had significantly better invasive disease–free survival compared with those treated with solvent-based paclitaxel (84% vs. 76.3%, P = .002). Event-free survival was also significantly improved with nab-paclitaxel, but overall survival did not appear to differ between the two arms. Treatment-related peripheral sensory neuropathy improved “much faster” with nab-paclitaxel at 125 mg/m2 than with nab-paclitaxel at 150 mg/m2.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.